General Proximity De-Stealths with $16M to Pioneer Next-Gen Induced Proximity Medicines for ‘Undruggable’ Targets
The company will use the capital to accelerate the development of treatments targeting undruggable proteins associated with cancer, cardiometabolic disease, neurodegeneration, and longevity SAN FRANCISCO, Jan. 3, 2025 /PRNewswire/ — General Proximity, a breakthrough biotech platform company, today…